A Study in Subjects With Liver Function Injury and Subjects With Normal Liver Function

Summary

Evaluate the pharmacokinetic differences of the main metabolite 116-N1 of JT001 in subjects with mild and moderate liver function impairment and those with normal liver function, providing a basis for formulating clinical medication plans for patients with liver function impairment;

Timeline

Start

2023-07-28

Primary completion

2023-08-18

Completion

2023-08-18

Publications

• Tan X, Lu T, Kuang S, Meng Q, Yu G, Zou J, Wang Y. Pharmacokinetics and Safety of VV116 in Subjects With Mild or Moderate Hepatic Impairment Compared With Healthy Controls: A Phase I, Open-Label Study. Clin Pharmacol Drug Dev. 2026 Feb;15(2):e70037. doi: 10.1002/cpdd.70037.

Drugs

Indications